1. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest. 1993; 91:950–960.

2. Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest. 1996; 97:540–550.
3. Damsky CH, Librach C, Lim KH, Fitzgerald ML, McMaster MT, Janatpour M, et al. Integrin switching regulates normal trophoblast invasion. Development. 1994; 120:3657–3666.

4. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol. 1992; 80:283–285.
5. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science. 1997; 277:1669–1672.

6. Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta. 2000; 21:Suppl A. S25–S30.

7. Caniggia I, Mostachfi H, Winter J, Gassmann M, Lye SJ, Kuliszewski M, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest. 2000; 105:577–587.
8. Zhou Y, Genbacev O, Damsky CH, Fisher SJ. Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia. J Reprod Immunol. 1998; 39:197–213.

9. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda). 2004; 19:176–182.

10. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004; 5:343–354.

11. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003; 9:677–684.

12. Maxwell P, Salnikow K. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther. 2004; 3:29–35.

13. Rajakumar A, Conrad KP. Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta. Biol Reprod. 2000; 63:559–569.
14. Matsuura S, Itakura A, Ohno Y, Nakashima Y, Murata Y, Takeuchi M, et al. Effects of estradiol administration on feto-placental growth in rat. Early Hum Dev. 2004; 77:47–56.

15. Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocr Rev. 1995; 16:608–648.

16. Cronier L, Guibourdenche J, Niger C, Malassiné A. Oestradiol stimulates morphological and functional differentiation of human villous cytotrophoblast. Placenta. 1999; 20:669–676.

17. Nickel EA, Hsieh CH, Chen JG, Schwacha MG, Chaudry IH. Estrogen suppresses cardiac IL-6 after trauma-hemorrhage via a hypoxia-inducible factor 1 alpha-mediated pathway. Shock. 2009; 31:354–358.
18. Mukundan H, Kanagy NL, Resta TC. 17-beta estradiol attenuates hypoxic induction of HIF-1alpha and erythropoietin in Hep3B cells. J Cardiovasc Pharmacol. 2004; 44:93–100.
19. Dawood MY, Ratnam SS. Serum unconjugated estradiol-17 beta in normal pregnancy measured by radioimmunoassay. Obstet Gynecol. 1974; 44:194–199.
20. Rajakumar A, Whitelock KA, Weissfeld LA, Daftary AR, Markovic N, Conrad KP. Selective overexpression of the hypoxia-inducible transcription factor, HIF-2alpha, in placentas from women with preeclampsia. Biol Reprod. 2001; 64:499–506.
21. Rajakumar A, Doty K, Daftary A, Harger G, Conrad KP. Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae. Placenta. 2003; 24:199–208.
22. Abdul-Karim RW, Nesbitt RE Jr, Drucker MH, Rizk PT. The regulatory effect of estrogens on fetal growth. I. Placental and fetal body weights. Am J Obstet Gynecol. 1971; 109:656–661.
23. Storment JM, Meyer M, Osol G. Estrogen augments the vasodilatory effects of vascular endothelial growth factor in the uterine circulation of the rat. Am J Obstet Gynecol. 2000; 183:449–453.

24. Ranta T, Stenman UH, Unnérus HA, Rossi J, Seppälä M. Maternal plasma prolactin levels in preeclampsia. Obstet Gynecol. 1980; 55:428–430.
25. Allen EI, Lachelin GC. A comparison of plasma levels of progesterone, oestradiol, unconjugated oestriol and total oestriol with urinary total oestrogen levels in clinical obstetric practice. Br J Obstet Gynaecol. 1978; 85:278–292.

26. Walsh SW. Progesterone and estradiol production by normal and preeclamptic placentas. Obstet Gynecol. 1988; 71:222–226.

27. Rosing U, Carlström K. Serum levels of unconjugated and total oestrogens and dehydroepiandrosterone, progesterone and urinary oestriol excretion in pre-eclampsia. Gynecol Obstet Invest. 1984; 18:199–205.

28. Acromite MT, Mantzoros CS, Leach RE, Hurwitz J, Dorey LG. Androgens in preeclampsia. Am J Obstet Gynecol. 1999; 180:60–63.

29. Troisi R, Potischman N, Roberts JM, Ness R, Crombleholme W, Lykins D, et al. Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. Int J Epidemiol. 2003; 32:455–460.

30. Smith GV, Smith OW. Estrogen and progestin metabolism in pregnancy. III. The effect of hormone administration in pre-eclampsia. J Clin Endocrinol. 1941; 1:477–484.
31. Mizutani S, Kurauchi O, Ito Y, Narita O, Tomoda Y. Positive effect of estradiol and progesterone in severe pre-eclampsia. Exp Clin Endocrinol. 1988; 92:161–170.

32. Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R. Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer. 2002; 87:971–973.

33. Ekbom A, Trichopoulos D, Adami HO, Hsieh CC, Lan SJ. Evidence of prenatal influences on breast cancer risk. Lancet. 1992; 340:1015–1018.

34. Takanashi K, Honma T, Kashiwagi T, Honjo H, Yoshizawa I. Detection and measurement of urinary 2-hydroxyestradiol 17-sulfate, a potential placental antioxidant during pregnancy. Clin Chem. 2000; 46:373–378.

35. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol. 2006; 291:R1085–R1093.
36. Molvarec A, Vér A, Fekete A, Rosta K, Derzbach L, Derzsy Z, et al. Association between estrogen receptor alpha (ESR1) gene polymorphisms and severe preeclampsia. Hypertens Res. 2007; 30:205–211.

37. Maruyama A, Nakayama T, Sato N, Mizutani Y, Furuya K, Yamamoto T. Association study using single nucleotide polymorphisms in the estrogen receptor beta (ESR2) gene for preeclampsia. Hypertens Res. 2004; 27:903–909.
38. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 2000; 19:173–179.
39. LaVallee TM, Zhan XH, Herbstritt CJ, Kough EC, Green SJ, Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 2002; 62:3691–3697.
40. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003; 3:363–375.

41. Casey ML, MacDonald PC. Characterization of catechol-O-methyltransferase activity in human uterine decidua vera tissue. Am J Obstet Gynecol. 1983; 145:453–457.

42. Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh). 1983; 103:282–288.

43. Barnea ER, MacLusky NJ, DeCherney AH, Naftolin F. Catechol-o-methyl transferase activity in the human term placenta. Am J Perinatol. 1988; 5:121–127.

44. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008; 453:1117–1121.

45. Yun SP, Lee MY, Ryu JM, Song CH, Han HJ. Role of HIF-1alpha and VEGF in human mesenchymal stem cell proliferation by 17beta-estradiol: involvement of PKC, PI3K/Akt, and MAPKs. Am J Physiol Cell Physiol. 2009; 296:C317–C326.